Patents Examined by Mark Halvorson
  • Patent number: 11987644
    Abstract: The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof, and methods of manufacturing such antibodies by co-expressing modified Fc-mutated derivatives of two different monoclonal antibodies in mammalian cell lines.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: May 21, 2024
    Assignee: NOVARTIS AG
    Inventors: Michael Otto Bardroff, Tina Buch, Christian Graf, Daniel Heitmann, Thomas Jostock, Hans-Peter Knopf, Rolf Koehler, Jiri Kovarik, Stephen John Oliver, Dhavalkumar Patel, Maximilian Woisetschlaeger
  • Patent number: 11974970
    Abstract: A muscular atrophy-inducing agent containing, as an active ingredient, a hypometabolism-inducing substance selected from the group consisting of 3-iodothyronamine (T1AM), [D-Ala2,D-Leu5] enkephalin (DADLE), 5?-adenosine monophosphate (5?-AMP), and hydrogen sulfide (H2S), and a method for preventing or treating muscular hypertrophy; and a method for shrinking facial muscle are proposed. The muscular atrophy study model can provide a study model for an economic muscular atrophy study by using a hypometabolism-inducing substance which can be mass-produced, has an effect which may be usefully used by verification for screening of a drug for preventing or treating muscular atrophy, and can be usefully used as a compositions for preventing or treating muscular hypertrophy and a composition for facial muscle shrinkage through the muscular atrophy effect.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: May 7, 2024
    Assignee: UNIVERSITY INDUSTRY FOUNDATION, YONSEI UNIVERSITY WONJU CAMPUS
    Inventors: Inho Choi, Chan-Moon Chung
  • Patent number: 11965021
    Abstract: The present application provides immune cells (such as T cells) comprising a chimeric antibody-T cell receptor (TCR) construct (caTCR) and a chimeric signaling receptor (CSR) construct. The caTCR comprises an antigen-binding module that specifically binds to a target antigen and a T cell receptor module (TCRM) capable of recruiting at least one TCR-associated signaling molecule, and the CSR comprises a ligand-binding domain that specifically binds to a target ligand and a co-stimulatory signaling domain capable of providing a stimulatory signal to the immune cell. Also provided are methods of making and using these cells.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: April 23, 2024
    Assignee: EUREKA THERAPEUTICS, INC.
    Inventors: Hong Liu, Pengbo Zhang, Lucas Horan, Yiyang Xu, Binnaz K. Staley, Lianxing Liu, Hongruo Yun
  • Patent number: 11958895
    Abstract: The present invention relates to broadly neutralizing anti-influenza monoclonal antibodies or antigen-binding fragments thereof. The present invention further relates to therapeutic uses of the isolated antibody or the antigen-binding fragment thereof.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: April 16, 2024
    Assignee: University of Rochester
    Inventors: James J. Kobie, Luis Martinez-Sobrido, Michael Piepenbrink, Aitor Nogales
  • Patent number: 11904002
    Abstract: Methods described herein relate to constructing therapeutic fusion-specific vaccine libraries, selecting a therapeutic fusion-specific vaccine for a cancer patient, and/or constructing a de novo therapeutic fusion-specific vaccine for patients having a gene fusion that is absent from a fusion-specific vaccine library.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: February 20, 2024
    Assignee: BostonGene Corporation
    Inventors: Maksym Artomov, Feliks Frenkel, Igor Golubev, Olga Zolotareva
  • Patent number: 11878053
    Abstract: The invention relates to prophylaxis and therapy of cancer. In particular there is provided a protein Tryptophan 2,3-dioxygenase (TDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of TDO or peptides derived thereof or TDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to TDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: January 23, 2024
    Assignee: IO Biotech ApS
    Inventor: Mads Hald Andersen
  • Patent number: 11873333
    Abstract: The present disclosure provides humanized antibodies and antigen-binding fragments thereof that specifically bind to SFRP2 and compositions comprising such humanized antibodies or antigen-binding fragments thereof. In some aspects, the humanized antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased SFRP2, such as cancer. In some aspects, the antibodies or antigen-binding fragments can be used to treat osteosarcoma.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: January 16, 2024
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Nancy Demore, Cam Patterson
  • Patent number: 11873344
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: January 16, 2024
    Assignees: Daiichi Sankyo Co., Ltd., Daiichi Sankyo Europe GmbH, Kinki University, Amgen, Inc.
    Inventors: Matthias Schneider, Sabine Blum, Renee Jeanne Mendell-Harary, Daniel J. Freeman, Robert Allen Beckman, Xiaoping Jin, Kimio Yonesaka, Kazuhiko Nakagawa
  • Patent number: 11840579
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: December 12, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Seung Chu, Gregory Moore, John Desjarlais
  • Patent number: 11840736
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: December 12, 2023
    Assignees: Daiichi Sankyo Co., Ltd., U3 Pharma GmbH, Amgen, Inc.
    Inventors: Matthias Schneider, Sabine Blum, Renee Jeanne Mendell-Harary, Daniel J. Freeman, Robert Allen Beckman, Xiaoping Jin
  • Patent number: 11833223
    Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: December 5, 2023
    Assignee: OBI PHARMA, INC.
    Inventors: Cheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen, Chiu-Chun Lin
  • Patent number: 11834511
    Abstract: The present disclosure provides compositions and uses thereof for treating a disease or disorder associated with CD20 expression. Treatments of this disclosure include use of a host cell expressing a fusion protein, such as an anti-CD20 CAR, optionally in combination with a CD20-specific binding molecule, a chemotherapeutic, an inhibitor of an immunosuppression component, or combinations thereof.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: December 5, 2023
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Oliver Press, Brian Till
  • Patent number: 11820825
    Abstract: The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 pM for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: November 21, 2023
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robertus Cornelis Roovers
  • Patent number: 11814679
    Abstract: The present disclosure provides methods and compositions relating to isolated CD8+ T cells expressing a disease antigen-specific T cell receptor, as well as nucleic acids encoding the V? and V? polypeptide pairs of T cell receptors (TCRs) of such disease antigen-specific T cells. Such disease antigen-specific CD8+ T cells are obtainable from the periphery (e.g., blood) of a subject having a disease amenable to treatment with an IL-10 agent. The present disclosure also contemplates therapeutic methods and compositions relating to administration of isolated disease antigen-specific CD8+ T cells to a subject, as well as therapeutic methods and compositions relating to CD8+ T cells genetically modified to express a disease antigen-specific TCR and/or chimeric antigen receptor.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: November 14, 2023
    Assignee: Eli Lilly and Company
    Inventors: John Brian Mumm, Ivan Ho Chan, Scott McCauley, Scott Ogg, Martin Oft
  • Patent number: 11807686
    Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: November 7, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Novotny, Jr., Nils Lonberg, Cyrus Hedvat, Raphael Clynes, Darren Locke, John P. Cogswell, Jeffrey Jackson, Christopher Harbison, Robin Edwards
  • Patent number: 11795222
    Abstract: This invention relates to the use of NKG2A-targeting agents for the treatment of cancers, notably head and neck cancers, in a patient having received prior treatment with cetuximab. This invention also provides advantageous combination regimens for use with NKG2A-targeting agents for the treatment of cancers.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: October 24, 2023
    Assignee: INNATE PHARMA
    Inventors: Agnes Boyer-Chammard, Pierre Dodion, Roger Cohen
  • Patent number: 11787864
    Abstract: The present invention provides Fc-fused protein constructs, which as monovalent dimers have a higher serum half-life compared to a native/natural molecule, and are, therefore, advantageous for achieving higher titers of the proteins during production, higher stability during storage, and improved efficacy when used as a therapeutic. Also provided are Fc-fused protein constructs having mutations in the Fc region that reduce effector functions, which have increased activity to inhibit tumor growth and are, therefore, advantageous when used as a cancer therapy.
    Type: Grant
    Filed: September 1, 2022
    Date of Patent: October 17, 2023
    Assignee: Dragonfly Therapeutics, Inc.
    Inventors: Ann F. Cheung, Jean-Marie Cuillerot, Asya Grinberg, Eva Gutierrez, William Haney, Nicolai Wagtmann
  • Patent number: 11785925
    Abstract: The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: October 17, 2023
    Assignees: THE BROAD INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Benjamin Levine Ebert, Jan Krönke, Steven A. Carr, Namrata D. Udeshi, Emma Fink
  • Patent number: 11766473
    Abstract: A therapeutic vaccine and a method of cancer treatment by inducing humoral and cellular immune responses against malignant cells is provided. The vaccine comprises a delivery system that incorporates at least one peptide whose sequence encompasses a genetic mutation associated with a malignancy (neoantigen), at least one immunostimulant, and at least one type of lipid molecule.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: September 26, 2023
    Assignee: Xeme Biopharma Inc.
    Inventors: Mircea C. Popescu, Richard J. Robb
  • Patent number: 11760801
    Abstract: The disclosure provided herein relates to monospecific and multispecific antibodies, that bind CEACAM1 and optionally CEACAM5 and/or CEACAM6, and methods of producing and using the described antibodies.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: September 19, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Wendell Lamar B Blackwell, Douglas V. Dolfi, Cassandra L. Lowenstein, Raluca I. Verona